XBI250103C79000
- 0.00
- 0.000.00%
SPDR S&P Biotech ETF Newsroom
Market Climbed Monday Just Past Santa Rally High Water Mark | Wall Street Today
AbbVie Announced Q4 2024 Earnings To Include $1.6B Acquired IPR&D Costs, Impacting EPS By $0.88; Final Results Pending; Q4 Adj EPS $2.06-$2.10; FY24 Adj EPS Guidance $10.02-$10.06
Why Moderna (MRNA) Stock Is Trading Higher
FDA Issues First Draft Guidance on Use of AI in Drug, Medical Device Development
Moderna CEO Letter Says With A Full Season Of RSV Contracting In 2025, Expect To Increase MRESVIA's Market Share In U.S. And Market Access Globally; Plan To Bring Manufacturing Plants Online In The UK, Canada And Australia In 2025
CES Tech Conference Week Starts with Nvidia and Chips Climbing | Live Stock
Healthcare Sector's 2024 Gainers and Losers: Intuitive Surgical, Boston Scientific Tops Chart
Citi's Themes: Top Stocks in AI, Leisure, Fin-tech, Video Gaming, Etc. Vs. Their SA Quant Ratings
Vaccine Stocks Gain Amid Uptick in Flu, COVID-19, RSV
SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?
Santa Clause Came and Went Without Bringing Gifts | Weekly Buzz
Friday? More Like Grinch Day | Wall Street Today
Natera Shares Are Trading Higher After Canaccord Genuity Raised Its Price Target on the Stock From $165 to $180.
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic
The S&P 500's 10 Worst Performing Stocks in 2023 Fell Again in 2024
Natera Analyst Ratings
Viking Therapeutics Among Potential Buyout Candidates: Oppenheimer
Best and Worst Performing S&P 500 Stocks in a Rosy Year for Index
Santa Claus Came Without Rallying the Troops | Live Stock
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields